ELE Biotech
Contact information
- Biomarkers
ELE Biotech develops ELEarly Dementia, an in vitro diagnostic solution based on blood analysis for the early detection and risk stratification of dementia associated with tauopathies. The solution is complemented by interpretation software to support clinical decision-making. Our goal is to facilitate its adoption in healthcare settings and contribute to a more anticipatory and sustainable medicine.
ELEarly Dementia analysis service for at-risk population/patients, in collaboration with healthcare centers and insurance companies.
ELEarly Dementia diagnostic kit (IVD, blood qPCR) for implementation in hospitals, clinical laboratories, and insurance companies.
Interpretation software to support risk stratification and integration of results in the clinical setting.
- Hospitals and clinical groups for evidence generation and integration into care pathways.
- Insurance companies and healthcare systems for screening and preventive medicine programs.
- Science parks and innovation centers for collaboration and infrastructure.
- Industrial partners for manufacturing/industrialization, quality control, and the kit supply chain.